Prevention of violence against women and girls: A cost-effectiveness study across 6 low- and middle-income countries.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2022
Historique:
received: 11 01 2021
accepted: 28 09 2021
entrez: 24 3 2022
pubmed: 25 3 2022
medline: 21 4 2022
Statut: epublish

Résumé

Violence against women and girls (VAWG) is a human rights violation with social, economic, and health consequences for survivors, perpetrators, and society. Robust evidence on economic, social, and health impact, plus the cost of delivery of VAWG prevention, is critical to making the case for investment, particularly in low- and middle-income countries (LMICs) where health sector resources are highly constrained. We report on the costs and health impact of VAWG prevention in 6 countries. We conducted a trial-based cost-effectiveness analysis of VAWG prevention interventions using primary data from 5 randomised controlled trials (RCTs) in sub-Saharan Africa and 1 in South Asia. We evaluated 2 school-based interventions aimed at adolescents (11 to 14 years old) and 2 workshop-based (small group or one to one) interventions, 1 community-based intervention, and 1 combined small group and community-based programme all aimed at adult men and women (18+ years old). All interventions were delivered between 2015 and 2018 and were compared to a do-nothing scenario, except for one of the school-based interventions (government-mandated programme) and for the combined intervention (access to financial services in small groups). We computed the health burden from VAWG with disability-adjusted life year (DALY). We estimated per capita DALYs averted using statistical models that reflect each trial's design and any baseline imbalances. We report cost-effectiveness as cost per DALY averted and characterise uncertainty in the estimates with probabilistic sensitivity analysis (PSA) and cost-effectiveness acceptability curves (CEACs), which show the probability of cost-effectiveness at different thresholds. We report a subgroup analysis of the small group component of the combined intervention and no other subgroup analysis. We also report an impact inventory to illustrate interventions' socioeconomic impact beyond health. We use a 3% discount rate for investment costs and a 1-year time horizon, assuming no effects post the intervention period. From a health sector perspective, the cost per DALY averted varies between US$222 (2018), for an established gender attitudes and harmful social norms change community-based intervention in Ghana, to US$17,548 (2018) for a livelihoods intervention in South Africa. Taking a societal perspective and including wider economic impact improves the cost-effectiveness of some interventions but reduces others. For example, interventions with positive economic impacts, often those with explicit economic goals, offset implementation costs and achieve more favourable cost-effectiveness ratios. Results are robust to sensitivity analyses. Our DALYs include a subset of the health consequences of VAWG exposure; we assume no mortality impact from any of the health consequences included in the DALYs calculations. In both cases, we may be underestimating overall health impact. We also do not report on participants' health costs. We demonstrate that investment in established community-based VAWG prevention interventions can improve population health in LMICs, even within highly constrained health budgets. However, several VAWG prevention interventions require further modification to achieve affordability and cost-effectiveness at scale. Broadening the range of social, health, and economic outcomes captured in future cost-effectiveness assessments remains critical to justifying the investment urgently required to prevent VAWG globally.

Sections du résumé

BACKGROUND
Violence against women and girls (VAWG) is a human rights violation with social, economic, and health consequences for survivors, perpetrators, and society. Robust evidence on economic, social, and health impact, plus the cost of delivery of VAWG prevention, is critical to making the case for investment, particularly in low- and middle-income countries (LMICs) where health sector resources are highly constrained. We report on the costs and health impact of VAWG prevention in 6 countries.
METHODS AND FINDINGS
We conducted a trial-based cost-effectiveness analysis of VAWG prevention interventions using primary data from 5 randomised controlled trials (RCTs) in sub-Saharan Africa and 1 in South Asia. We evaluated 2 school-based interventions aimed at adolescents (11 to 14 years old) and 2 workshop-based (small group or one to one) interventions, 1 community-based intervention, and 1 combined small group and community-based programme all aimed at adult men and women (18+ years old). All interventions were delivered between 2015 and 2018 and were compared to a do-nothing scenario, except for one of the school-based interventions (government-mandated programme) and for the combined intervention (access to financial services in small groups). We computed the health burden from VAWG with disability-adjusted life year (DALY). We estimated per capita DALYs averted using statistical models that reflect each trial's design and any baseline imbalances. We report cost-effectiveness as cost per DALY averted and characterise uncertainty in the estimates with probabilistic sensitivity analysis (PSA) and cost-effectiveness acceptability curves (CEACs), which show the probability of cost-effectiveness at different thresholds. We report a subgroup analysis of the small group component of the combined intervention and no other subgroup analysis. We also report an impact inventory to illustrate interventions' socioeconomic impact beyond health. We use a 3% discount rate for investment costs and a 1-year time horizon, assuming no effects post the intervention period. From a health sector perspective, the cost per DALY averted varies between US$222 (2018), for an established gender attitudes and harmful social norms change community-based intervention in Ghana, to US$17,548 (2018) for a livelihoods intervention in South Africa. Taking a societal perspective and including wider economic impact improves the cost-effectiveness of some interventions but reduces others. For example, interventions with positive economic impacts, often those with explicit economic goals, offset implementation costs and achieve more favourable cost-effectiveness ratios. Results are robust to sensitivity analyses. Our DALYs include a subset of the health consequences of VAWG exposure; we assume no mortality impact from any of the health consequences included in the DALYs calculations. In both cases, we may be underestimating overall health impact. We also do not report on participants' health costs.
CONCLUSIONS
We demonstrate that investment in established community-based VAWG prevention interventions can improve population health in LMICs, even within highly constrained health budgets. However, several VAWG prevention interventions require further modification to achieve affordability and cost-effectiveness at scale. Broadening the range of social, health, and economic outcomes captured in future cost-effectiveness assessments remains critical to justifying the investment urgently required to prevent VAWG globally.

Identifiants

pubmed: 35324910
doi: 10.1371/journal.pmed.1003827
pii: PMEDICINE-D-21-00158
pmc: PMC8946747
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003827

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: CW was the Chief Scientific Adviser at the Department for International Development (UKAid) at the time of writing. This work was conducted as part of her academic role as professor in epidemiology at the London School of Hygiene & Tropical Medicine.

Références

BMC Public Health. 2016 Feb 29;16:196
pubmed: 26924488
PLoS Med. 2020 Apr 17;17(4):e1003056
pubmed: 32302308
Trauma Violence Abuse. 2020 Dec 8;:1524838020976088
pubmed: 33287669
BMJ Glob Health. 2020 Dec;5(12):
pubmed: 33355268
BMC Public Health. 2014 Dec 29;14:1325
pubmed: 25544716
J Interpers Violence. 2021 Nov;36(21-22):NP11392-NP11420
pubmed: 31702407
BMJ Glob Health. 2018 Nov 5;3(6):e000964
pubmed: 30483412
Bull World Health Organ. 2009 Nov;87(11):824-32
pubmed: 20072767
Value Health. 2017 Apr;20(4):699-704
pubmed: 28408014
Lancet. 2002 Apr 13;359(9314):1331-6
pubmed: 11965295
AIDS. 2014 Jan 28;28(3):425-34
pubmed: 24670525
PLoS One. 2017 Aug 17;12(8):e0180833
pubmed: 28817565
BMJ. 2008 Aug 07;337:a506
pubmed: 18687720
Glob Health Action. 2017 Jan - Dec;10(sup2):1290427
pubmed: 28467193
Prev Sci. 2017 Oct;18(7):818-827
pubmed: 27562036
Glob Health Action. 2014 May 15;7:23431
pubmed: 24848654
Health Policy Plan. 2011 Sep;26(5):366-72
pubmed: 20974751
Sex Transm Infect. 2004 Dec;80 Suppl 2:ii43-8
pubmed: 15572639
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
BMC Public Health. 2019 Jun 27;19(1):834
pubmed: 31248392
Lancet. 2006 Dec 2;368(9551):1973-83
pubmed: 17141704
J Glob Health. 2020 Jun;10(1):010406
pubmed: 32257154
Lancet Glob Health. 2015 Jul;3(7):e378-86
pubmed: 26087985
Glob Health Sci Pract. 2017 Mar 28;5(1):115-137
pubmed: 28351880
J Adolesc Health. 2020 Mar;66(3):323-335
pubmed: 31784410
Health Policy Plan. 2020 Aug 1;35(7):855-866
pubmed: 32556173
Lancet Child Adolesc Health. 2021 Mar;5(3):223-232
pubmed: 33220790
BMJ Open. 2021 Mar 29;11(3):e042365
pubmed: 33782020
Glob Health Action. 2019;12(1):1612604
pubmed: 31134866
Glob Health Action. 2020;13(1):1711336
pubmed: 31935166
BMC Med. 2014 Jul 31;12:122
pubmed: 25248996
Lancet. 2022 Feb 26;399(10327):803-813
pubmed: 35182472
BMJ Glob Health. 2020 Mar 16;5(3):e001946
pubmed: 32201622

Auteurs

Giulia Ferrari (G)

London School of Economics and Political Science, London, United Kingdom.
London School of Hygiene & Tropical Medicine, London, United Kingdom.
University of Bristol, Bristol Medical School, Bristol, United Kingdom.

Sergio Torres-Rueda (S)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Esnat Chirwa (E)

Gender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.

Andrew Gibbs (A)

Gender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.

Stacey Orangi (S)

Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.

Edwine Barasa (E)

Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Theresa Tawiah (T)

Kintampo Health Research Centre, Kintampo, Ghana.

Rebecca Kyerewaa Dwommoh Prah (RK)

Kintampo Health Research Centre, Kintampo, Ghana.

Regis Hitimana (R)

School of Public Health, University of Rwanda, Kigali, Rwanda.

Emmanuelle Daviaud (E)

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Eleonah Kapapa (E)

National Institute of Public Administration, Lusaka, Zambia.

Kristin Dunkle (K)

Gender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.

Lori Heise (L)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Erin Stern (E)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Sangeeta Chatterji (S)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Benjamin Omondi (B)

Ujamaa Africa, Nairobi, Kenya.

Deda Ogum Alangea (D)

Department of Population Family & Reproductive Health, School of Public Health, College of Health Sciences, University of Ghana, Legon, Ghana.

Rozina Karmaliani (R)

Department of Community Health Science, Aga Khan University, Karachi, Pakistan.
School of Nursing & Midwifery, Aga Khan University, Karachi, Pakistan.

Hussain Maqbool Ahmed Khuwaja (H)

School of Nursing & Midwifery, Aga Khan University, Karachi, Pakistan.

Rachel Jewkes (R)

Gender and Health Research Unit, South African Medical Research Council, Cape Town, South Africa.

Charlotte Watts (C)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Anna Vassall (A)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH